US giant OneThree Biotech will lend Open Orphan spinout its state-of-the-art technology to accelerate treatment of severe respiratory infection RSV
Poolbeg Pharma, the infectious disease pharmaceutical company, has signed a deal with OneThree Biotech, a US artificial intelligence (AI) company, to identify new drug treatments for a contagious virus that affects 50 million people every year.
The company believes the deal will help rapidly identify new drugs and treatments for for Respiratory Syncytial Virus (RSV), which it said should yield a significant amount of shareholder value.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
